Invesaro

Stocks Comparison

Maxcyte vs Nrc Health: revenue, profit, margins and growth compared

Maxcyte brought in $33M of revenue in fiscal 2025, Nrc Health $137.4M in fiscal 2025. Revenue changed by -14.5% at Maxcyte and -4.0% at Nrc Health on the year before, so Nrc Health grew faster. Maxcyte kept -135.1% of its revenue as net profit, Nrc Health 8.2%. Free cash flow was -$36.2M at Maxcyte and $15.7M at Nrc Health.

Side by side, latest fiscal year

MXCTNRC
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$33M$137.4M
Revenue growth-14.5%-4.0%
Net income-$44.6M$11.3M
Net margin-135.1%8.2%
Free cash flow-$36.2M$15.7M
Free cash flow margin-109.5%11.5%
Earnings per share (diluted)-$0.42$50.00
Cash$20.1M$4.1M
Debtn/a$79M
Price to earningsn/a0.4
Market value$120.8M$432.9M
Dividend yieldn/a2.66%
Rank by revenue in sector#390 of 523 · Health care#278 of 523 · Health care

Over the years

Revenue
MXCT FY2019: $21.6MMXCT FY2021: $26.2MMXCT FY2021: $33.9MMXCT FY2022: $44.3MMXCT FY2023: $41.3MMXCT FY2024: $38.6MMXCT FY2025: $33MNRC FY2018: $119.7MNRC FY2019: $128MNRC FY2020: $133.3MNRC FY2021: $148MNRC FY2022: $151.6MNRC FY2023: $148.6MNRC FY2024: $143.1MNRC FY2025: $137.4MFY18FY19FY20FY21FY22FY23FY24FY25
MXCT $33MNRC $137.4M
Net income
MXCT FY2019: -$12.9MMXCT FY2021: -$11.8MMXCT FY2021: -$19.1MMXCT FY2022: -$23.6MMXCT FY2023: -$37.9MMXCT FY2024: -$41.1MMXCT FY2025: -$44.6MNRC FY2018: $30MNRC FY2019: $32.4MNRC FY2020: $37.2MNRC FY2021: $37.4MNRC FY2022: $31.8MNRC FY2023: $31MNRC FY2024: $24.8MNRC FY2025: $11.3MFY18FY19FY20FY21FY22FY23FY24FY25
MXCT -$44.6MNRC $11.3M
Net margin
MXCT FY2019: -59.6%MXCT FY2021: -45.2%MXCT FY2021: -56.3%MXCT FY2022: -53.3%MXCT FY2023: -91.8%MXCT FY2024: -106.3%MXCT FY2025: -135.1%NRC FY2018: 25.1%NRC FY2019: 25.3%NRC FY2020: 27.9%NRC FY2021: 25.3%NRC FY2022: 21.0%NRC FY2023: 20.8%NRC FY2024: 17.3%NRC FY2025: 8.2%FY18FY19FY20FY21FY22FY23FY24FY25
MXCT -135.1%NRC 8.2%
Revenue growth
MXCT FY2021: +21.0%MXCT FY2021: +29.5%MXCT FY2022: +30.6%MXCT FY2023: -6.7%MXCT FY2024: -6.4%MXCT FY2025: -14.5%NRC FY2019: +6.9%NRC FY2020: +4.1%NRC FY2021: +11.0%NRC FY2022: +2.4%NRC FY2023: -2.0%NRC FY2024: -3.7%NRC FY2025: -4.0%FY19FY20FY21FY22FY23FY24FY25
MXCT -14.5%NRC -4.0%
Free cash flow
MXCT FY2019: -$10.1MMXCT FY2021: -$10.9MMXCT FY2021: -$14.5MMXCT FY2022: -$33.3MMXCT FY2023: -$25.4MMXCT FY2024: -$29.3MMXCT FY2025: -$36.2MNRC FY2018: $33.9MNRC FY2019: $36.3MNRC FY2020: $36.7MNRC FY2021: $40.8MNRC FY2022: $26.4MNRC FY2023: $22.3MNRC FY2024: $19.2MNRC FY2025: $15.7MFY18FY19FY20FY21FY22FY23FY24FY25
MXCT -$36.2MNRC $15.7M

Fiscal years as each company reports them; the two may end in different months.

Questions about Maxcyte and Nrc Health

Which is bigger by revenue, Maxcyte or Nrc Health?

Nrc Health is bigger by revenue: $137.4M in fiscal 2025, against $33M for Maxcyte in fiscal 2025.

Which keeps more of its revenue as profit, Maxcyte or Nrc Health?

Maxcyte had a net margin of -135.1% in fiscal 2025; Nrc Health had 8.2% in fiscal 2025.

Which grew revenue faster, Maxcyte or Nrc Health?

In their latest fiscal years revenue changed by -14.5% at Maxcyte and -4.0% at Nrc Health.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies